News

Filter

Forest Labs to spend $2.9 billion on acquiring Aptalis

Forest Labs to spend $2.9 billion on acquiring Aptalis

09-01-2014

Confirming recent speculative reports, US drugmaker Forest Laboratories says it has entered into a definitive…

AptalisForest LaboratoriesGastro-intestinalsMergers & AcquisitionsPharmaceuticalRare diseases

Ipsen prepares for EU resupply of Increlex; enters deal with Mayoly Spindler

Ipsen prepares for EU resupply of Increlex; enters deal with Mayoly Spindler

18-12-2013

French drugmaker Ipsen says that Lonza has successfully re-manufactured the active ingredient of Increlex…

Anti-Arthritics/RheumaticsEuropeGastro-intestinalsIncrelexIpsenLonzaMarkets & MarketingMayoly SpindlerPharmaceuticalProductionRare diseases

Salix Pharma moves into diabetes with $2.6 billion buy of Santarus

Salix Pharma moves into diabetes with $2.6 billion buy of Santarus

08-11-2013

Salix Pharmaceuticals has entered into a definitive merger agreement to acquire all the outstanding common…

DiabetesGastro-intestinalsGlumetzaMergers & AcquisitionsPharmaceuticalRare diseasesRuconestSalix PharmaceuticalsSantarus

Nycomed files for EU appro of SBS drug Revestive

29-03-2011

Privately-held Swiss drugmaker Nycomed has submitted a Marketing Authorization Application (MAA) to the…

EuropeGastro-intestinalsNPS PharmaceuticalsNycomedPharmaceuticalRare diseasesRegulationRevestiveteduglutide

Shire says 2nd-qtr 2010 revenues rose 35% and EPS leapt 71%; updates on Firazyr; Movetis’ Resolor cleared in Switzerland

05-08-2010

UK specialty drugmaker Shire, which has moved its headquarters to Ireland for tax reasons, posted rocketing…

BiotechnologyFinancialFirazyrGastro-intestinalsMovetisPharmaceuticalRare diseasesRegulationResearchResolorShire

COMPANY SPOTLIGHT

Menarini

Back to top